Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe

Herminia Gonzalez-Navarro1, Marian Vila-Caballer, Maria F Pastor

  • 1Vascular Biology Laboratory, Department of Molecular and Cellular Pathology and Therapy, Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain.

Insights

Insulin receptor substrate 2 (IRS2) deficiency exacerbates atherosclerosis in mice with hypercholesterolemia, independent of high blood sugar. This suggests IRS2 dysfunction may drive atherosclerosis in individuals with insulin resistance.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Disease Research
  • Immunology

Background:

  • Atherosclerosis is more prevalent in type 2 diabetes, but mechanisms are unclear.
  • Insulin receptor substrate 2 (IRS2)-deficient mice model type 2 diabetes, offering insight into metabolic derangements.
  • Understanding the link between insulin signaling and atherosclerosis is crucial.

Purpose of the Study:

  • To investigate the role of defective insulin signaling in atherosclerosis development.
  • To explore the interplay between insulin resistance, hypercholesterolemia, and atherosclerotic lesion progression.

Main Methods:

  • Utilized fat-fed mice models: wild-type, Irs2-null, apolipoprotein E-null (apoE-/-), and doubly-deficient apoE-/- Irs2-/-.
  • Assessed glucose levels, insulin levels, and atherosclerotic lesion development.
  • Correlated circulating insulin levels with atherosclerotic burden.

Main Results:

  • ApoE-/- Irs2-/- mice exhibited hyperinsulinemia but not hyperglycemia, unlike Irs2-/- mice.
  • Atherosclerosis was minimal in wild-type and Irs2-/- mice with moderate hypercholesterolemia.
  • Atherosclerosis was significantly enhanced in apoE-/- Irs2-/- mice compared to apoE-/- mice, despite similar severe hypercholesterolemia.
  • Circulating insulin levels positively predicted atherosclerotic lesion size in apoE-/- Irs2-/- mice.

Conclusions:

  • Hyperinsulinemia, driven by IRS2 deficiency, promotes atherosclerosis in the presence of severe hypercholesterolemia, even without hyperglycemia.
  • IRS2 is implicated as a key modulator of atherosclerosis development in hypercholesterolemic conditions.
  • Further research is needed to explore IRS2's role in normoglycemic, pre-diabetic individuals with insulin resistance.